MobileODT Overview
MobileODT develops optical diagnostic devices and software services designed for early cancer detection and a range of other medical purposes. The company is creating advanced optical technology components to turn smartphones into easy-to-use mobile point-of-care tools to help detect cancer and capture a range of biomedical images for diagnostic and other analytical purposes. Mobile ODT also develops intuitive app-based programs to operate its devices and connect them to a cloud-based software platform. The platform will enable immediate remote consultation with experts for improved case management and easy integration with a range of emerging electronic health record programs. The company’s EVA COLPO is an FDA-cleared, internet-connected portable colposcope that is as simple to use as a mobile phone. The device combines advanced hardware with integrated software to serve a variety of clinical needs. The EVA SANE is a secure and easy-to-use forensic documentation system for fast examinations. It combines the capabilities of a video colposcope and a digital camera to enable both full-body and external body cavity image and video capture. The EVA WELL is an FDA-cleared and HIPAA-compliant digital visualization tool for gynecologic exams.
Cumulative Funding Raised Over Time ($)
$4.0MAug 2020
$16.0MNov 2019
$16.9MSep 2014
Latest News
growth-positive
MobileODT Wins MedTech Breakthrough Imaging Award
MobileODT has been selected as the winner of the Best New Imaging Technology Solution award in the MedTech Breakthrough Awards program. The companys EVA System combines advanced imaging, data, and software applications to provide a new paradigm in cervical cancer screening and diagnostics. Their EVA VisualCheck AI technology uses artificial intelligence and machine learning to perform cervical cancer screening at scale, offering improved accuracy and speed. The award is a validation of MobileODTs momentum and their mission to support the World Health Organizations goal of eliminating cervical cancer by 2030. The MedTech Breakthrough Awards recognize excellence and innovation in the health and medical technology market.
Customers
growth-positive
FemTech Company MobileODT Announces the Release of a Next Generation AI Algorithm for Cervical Cancer Screening.
Israeli FemTech company MobileODT has announced the release of its next generation VisualCheck Artificial Intelligence Algorithm for cervical cancer screening. The algorithm provides results in less than 60 seconds and has been trained on pathology results and human annotated images. It improves the sensitivity and specificity of the screening process, offering users a more accurate screening tool. The algorithm has been validated by leading colposcopists and will be presented at the EUROGIN Conference in May. MobileODT is a digital health company that helps clinicians utilize AI on its portable EVA mini-colposcope to enhance womens health. The company has received investment capital from Orbimed, Tristel, Tara Health, Laerdal, DAI, and others.
Customers
growth-positive
Israeli FemTech Company MobileODT, To Be Participating In India's Largest Cervical Cancer Screening Program
MobileODTs EVA cervical screening technology is supporting a national cervical cancer screening project in India, which will be the most comprehensive and largest program of its kind in the country. The project is being run by Karkinos Healthcare in collaboration with GenWorks Health, MobileODTs exclusive distributor in India. The partnership will adopt the World Health Organizations recommended HPV DNA test for early detection of cervical cancer. MobileODTs EVA device will be used for colposcopy exams. The project aims to provide services to all women between the ages of 30 and 65 in India. MobileODT is proud to be part of this endeavor to eliminate cervical cancer in India.
Customers
growth-positive
Israeli tech wins praise for saving hundreds of Dominican women from cancer
Israeli femtech firm MobileODT has launched a large-scale nationwide campaign in the Dominican Republic to screen 50,000 women for cervical cancer using their EVA Visual Check AI technology. The technology allows non-specialists to diagnose abnormal cervical findings in their early stages using an ordinary smartphone and match patients with adequate preventive treatment. The campaign has already screened over 18,000 women, many of them of modest means. The project was made possible thanks to the efforts of the Israeli ambassador in the country. MobileODTs EVA System kit, which received FDA approval in 2016, is sold in about 30 countries and is in use in 60 clinics in the U.S.
CustomersPartners
growth-positive
Israeli FemTech Company MobileODT, Engaged in Large Scale Government Cervical Cancer Screening Project
MobileODTs Visual Check AI technology is supporting a large-scale government cervical cancer screening project in the Dominican Republic. The project, run by the Dominican Republic Ministry of Health in cooperation with MobileODT, has successfully screened 9,000 women in the past three months. Due to its initial success, the program will be expanded to cover another 50,000 women over the next 6 months. The Visual Check AI technology provides non-specialists with a clinical decision support tool for cervical cancer diagnosis. The company aims to develop groundbreaking AI solutions in the FemTech market and is currently in a funding round to support its long-term strategy. MobileODT has raised $26 million to date from various investors.
Customers
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $22.48M |
| Last funding | $2.3M |
| Stage | Mature |
| Rounds | 7 |
| Investors | 6 |
Team Members
1
Employees: 1-10
Web & Social Links
| Website | www.mobileodt.com |
| Careers | Careers page |
| Google Play | Google Play |
Locations
Ben Avigdor Street 8, Tel Aviv-Yafo, Israel
1732 1st Avenue, New York, NY 10128, USA
Photos & Videos
6 item(s)
MobileODT Business
Business models
B2B
Product stage
Released
Employees
1-10
Sector
Health Tech & Life SciencesDigital HealthcareDigital Medical DiagnosticsTarget Customer
Healthcare & Life SciencesHealthcareProvidersCore Technology
Platforms & InterfacesSoftwareArtificial IntelligenceMachine LearningTags (27)
non-invasiveearly-detectiondigital-healthcarewomen-healthmhealthdoctorselectro-opticsimagingdiagnosticsmachine-learningdata-analyticscanceroncologyhospitalsmobile-applicationshealthcare-providersclinical-trialsimage-processingdecision-supportartificial-intelligencetelehealthmedical-technologiesoptronicsclinicspatient-engagementwomenfemtechGeographic Markets
KenyaColombiaEl SalvadorIndiaMexicoEthiopiaEcuadorBelizeEuropeNicaraguaSouth KoreaBrazilArgentinaTanzaniaGlobalCentral AmericaUnited StatesCosta RicaDominican RepublicSouth AfricaPeruGuatemalaSouth AmericaAfricaPanamaMobileODT Financials
$22.48M
Total funding
Undisclosed
Capital raised
$2.3M
Last funding
Mature
Funding stage
7
Total rounds
6
Investors
Cumulative Funding Raised Over Time ($)
$4.0MAug 2020
$16.0MNov 2019
$16.9MSep 2014
Private Equity Funding
C Round
Aug 2020
$4M
OrbiMed (Lead)
,
Tristel, Tara Health Foundation, Laerdal Global
B Round
Nov 2019
$12M
OrbiMed (Lead)
,
Sanford Biosciences, Tristel, Tara Health Foundation, Laerdal Global
Seed
Sep 2014
$950K
iVentures Asia
Non-Equity Funding
GrantEvent
Jan 2021
$2.3M
National Cancer Institute
GrantEvent
Sep 2017
$25K
Vizient
GrantEvent
Oct 2015
$200K
MedTech Innovator
GrantEvent
Aug 2015
$3M
MedTech Innovator, Vodafone Americas Foundation
MobileODT Lifecycle
Cumulative Funding Raised Over Time
$4.0MAug 2020
$16.0MNov 2019
$16.9MSep 2014
All Events
C Round
Aug 2020
$4M
OrbiMed (Lead)
,
Tristel, Tara Health Foundation, Laerdal Global
B Round
Nov 2019
$12M
OrbiMed (Lead)
,
Sanford Biosciences, Tristel, Tara Health Foundation, Laerdal Global
Seed
Sep 2014
$950K
iVentures Asia
GrantEvent
Jan 2021
$2.3M
National Cancer Institute
GrantEvent
Sep 2017
$25K
Vizient
GrantEvent
Oct 2015
$200K
MedTech Innovator
GrantEvent
Aug 2015
$3M
MedTech Innovator, Vodafone Americas Foundation
MobileODT News
33 articles
growth-positive
MobileODT Wins MedTech Breakthrough Imaging Award
MobileODT has been selected as the winner of the Best New Imaging Technology Solution award in the MedTech Breakthrough Awards program. The companys EVA System combines advanced imaging, data, and software applications to provide a new paradigm in cervical cancer screening and diagnostics. Their EVA VisualCheck AI technology uses artificial intelligence and machine learning to perform cervical cancer screening at scale, offering improved accuracy and speed. The award is a validation of MobileODTs momentum and their mission to support the World Health Organizations goal of eliminating cervical cancer by 2030. The MedTech Breakthrough Awards recognize excellence and innovation in the health and medical technology market.
Customers
growth-positive
FemTech Company MobileODT Announces the Release of a Next Generation AI Algorithm for Cervical Cancer Screening.
Israeli FemTech company MobileODT has announced the release of its next generation VisualCheck Artificial Intelligence Algorithm for cervical cancer screening. The algorithm provides results in less than 60 seconds and has been trained on pathology results and human annotated images. It improves the sensitivity and specificity of the screening process, offering users a more accurate screening tool. The algorithm has been validated by leading colposcopists and will be presented at the EUROGIN Conference in May. MobileODT is a digital health company that helps clinicians utilize AI on its portable EVA mini-colposcope to enhance womens health. The company has received investment capital from Orbimed, Tristel, Tara Health, Laerdal, DAI, and others.
Customers
growth-positive
Israeli FemTech Company MobileODT, To Be Participating In India's Largest Cervical Cancer Screening Program
MobileODTs EVA cervical screening technology is supporting a national cervical cancer screening project in India, which will be the most comprehensive and largest program of its kind in the country. The project is being run by Karkinos Healthcare in collaboration with GenWorks Health, MobileODTs exclusive distributor in India. The partnership will adopt the World Health Organizations recommended HPV DNA test for early detection of cervical cancer. MobileODTs EVA device will be used for colposcopy exams. The project aims to provide services to all women between the ages of 30 and 65 in India. MobileODT is proud to be part of this endeavor to eliminate cervical cancer in India.
Customers
growth-positive
Israeli tech wins praise for saving hundreds of Dominican women from cancer
Israeli femtech firm MobileODT has launched a large-scale nationwide campaign in the Dominican Republic to screen 50,000 women for cervical cancer using their EVA Visual Check AI technology. The technology allows non-specialists to diagnose abnormal cervical findings in their early stages using an ordinary smartphone and match patients with adequate preventive treatment. The campaign has already screened over 18,000 women, many of them of modest means. The project was made possible thanks to the efforts of the Israeli ambassador in the country. MobileODTs EVA System kit, which received FDA approval in 2016, is sold in about 30 countries and is in use in 60 clinics in the U.S.
CustomersPartners
growth-positive
Israeli FemTech Company MobileODT, Engaged in Large Scale Government Cervical Cancer Screening Project
MobileODTs Visual Check AI technology is supporting a large-scale government cervical cancer screening project in the Dominican Republic. The project, run by the Dominican Republic Ministry of Health in cooperation with MobileODT, has successfully screened 9,000 women in the past three months. Due to its initial success, the program will be expanded to cover another 50,000 women over the next 6 months. The Visual Check AI technology provides non-specialists with a clinical decision support tool for cervical cancer diagnosis. The company aims to develop groundbreaking AI solutions in the FemTech market and is currently in a funding round to support its long-term strategy. MobileODT has raised $26 million to date from various investors.
Customers
growth-positive
FemTech Company MobileODT awarded prestigious National Cancer Institute (NCI) SBIR grant of $2.3 million
MobileODT, a FemTech company specializing in cervical screening, has been awarded a $2.3 million grant from the United States National Cancer Institute (NCI). The grant will be used to perform a large-scale clinical trial to validate the efficacy of MobileODTs EVA VisualCheck AI technology for cervical screening. The trial will compare the AI technology to standard methods such as Pap smear and visual inspection of the cervix. The trial will be conducted in cooperation with the Basic Health International organization (BHI) on a population of 10,000 subjects. The results of the trial are expected to bring MobileODTs technology to the forefront of womens health, especially in light of the World Health Organizations recent decision to accelerate the elimination of cervical cancer. MobileODT has received investment capital from Orbimed, Tristel, Tara Health, Laerdal, DAI, and others.
Investment
growth-positive
MobileODT completed $4 million series round C
MobileODT, the developer of the EVA System for cervical cancer screening, has completed a $4 million series C fundraising round. The funding will be used to further develop an AI clinical decision support technology for cervical cancer evaluation. The round was led by OrbiMed Israel Partners, with participation from Tristel, Tara Health, and Laerdal. MobileODT has raised a total of $26 million to date. The company aims to make quality screening more accessible and reduce unnecessary deaths from cervical cancer. The newly appointed CEO, Leon A. Boston, believes that launching the AI technology, VisualCheck, will be a game changer in womens health. The company has completed initial validation of VisualCheck and plans to release it later this year.
Investment
growth-negative
Medical tech dispute illuminates power struggle between entrepreneurs, investors
A dispute has arisen between shareholders of Israeli medical device startup MobileODT and lead investor OrbiMed. The dispute centers around OrbiMeds alleged attempt to pull out of a signed investment agreement with MobileODT and the claim that OrbiMeds representatives on the board acted in the interests of the VC fund rather than the company. The disagreement has led to threats of litigation. MobileODT, founded in 2012, has developed a smartphone-based system for detecting cervical cancer. The company has achieved regulatory approval, raised $22 million in funding, and sold its products for $2.4 million. OrbiMed first invested in MobileODT in 2017 and later entered into a share purchase agreement to invest $9 million. The dispute has resulted in the shutdown of company activities and unpaid leave for employees.
InvestmentManagement ChangesLayoffs
growth-positive
Saving Lives With AI: Israeli Femtech Firm Offers Cervical Cancer Screenings With Mobile Device
Israeli startup MobileODT is developing AI-based cervical cancer screening technology called VisualPap. The company recently announced a second round of institutional financing to support the launch of VisualPap. The test will be conducted using MobileODTs Enhanced Visual Assessment System (EVA System) digital colposcope. The EVA System combines advanced hardware with integrated software and is already being used in over 27 countries. The AI-powered algorithm used by the system has shown promising results in detecting cervical cancer. MobileODTs technology aims to make cervical cancer screening more comfortable, accessible, and cost-effective, particularly in developing countries. The company also plans to expand its technology to other fields of healthcare.
CustomersInvestment
growth-positive
Beyond the pap smear: What women need to know about preventing cervical cancer
The article discusses the importance of cervical cancer screening and highlights the effectiveness of the EVA test in detecting possible cases of cervical cancer. The Senior Obstetrician & Gynecologist at Apollo FirstMed Hospital in Chennai conducted a study that showed the EVA test to be more effective than the pap smear. However, the challenge lies in the lack of awareness about cervical cancer and the EVA test. The article emphasizes the importance of early screening and regular monitoring to prevent and treat cervical cancer. The EVA test, along with the pap smear, is an affordable option for screening. The article is produced by TNM Brand Studio in association with Apollo Hospitals.
Customers
growth-positive
Beyond the Pap smear: Startup uses phone, light and AI to detect cervical cancer
Israeli start-up MobileODT has developed a mobile digital colposcope called the Eva System, which uses an Automated Visual Evaluation (AVE) algorithm to detect cervical cancer. The algorithm has proven to be more reliable than human experts in identifying abnormal tissue. The device is a smartphone equipped with a light source, a lens for magnification, and the AVE algorithm. It can be used in any clinic and medical practice, providing precise screening tests for women in low-resource areas. The EVA system is already in use in 29 countries and 50 healthcare systems across the US. MobileODT recently achieved integration with the EMR of athenahealth. The company plans to start a pilot study in India and has partnered with Apollo Hospitals and Genworks Health.
CustomersPartnersInvestment
growth-positive
Beyond the Pap smear: Startup uses phone, light and AI to detect cervical cancer
Israeli start-up MobileODT has developed a mobile digital colposcope called Eva System that uses an Automated Visual Evaluation (AVE) algorithm to detect cervical cancer. The algorithm has proved to be more reliable than human experts in identifying abnormal tissue. The device, which is a smartphone equipped with a light source and a lens for magnification, allows for precise screening tests and can be used in any clinic or medical practice. MobileODTs Eva System is already in use in 29 countries and 50 healthcare systems across the US. The company plans to conduct a pilot study in India and has partnered with Apollo Hospitals and Genworks Health. MobileODT has raised $11 million in funding so far.
CustomersPartnersInvestment
growth-positive
MobileODT touts colposcope-based cervical cancer detection AI
MobileODT is implementing a new artificial intelligence algorithm in its EVA system Colposcope to detect cervical cancer more effectively. The algorithm, known as Automated Visual Evaluation (AVE), has been validated by the National Cancer Institute and the National Library of Medicine. MobileODT is working with the NCI and other researchers to validate the clinical application of the AVE algorithm through a large-scale pilot study with partners at Genworks Health and Apollo Hospitals in India. The study aims to investigate the use of the AI algorithm in detecting cervical cancer in up to 250 women. MobileODT is optimistic that the trial data will improve the effectiveness of the AVE technology.
PartnersExpand
growth-positive
https://www.jpost.com/Israel-News/Game-changing-Israeli-AI-revolutionizes-cervical-cancer-screening-577334
Israeli health tech company MobileODT has developed an augmented intelligence algorithm that can detect cervical cancer based on a single image. The algorithm, called Automated Visual Evaluation (AVE), has been validated by the National Cancer Institute and National Library of Medicine. It can identify problematic lesions more quickly and reliably than traditional Pap tests. MobileODTs EVA colposcope, which is approved by the US Food and Drug Administration, can deliver the AVE algorithm at the point of care. The companys solution is cheaper than other cervical cancer screening methods and provides accurate results within seconds. MobileODT has announced a pilot program with Indian partners Genworks Health and Apollo Hospital to validate the clinical application of the AVE algorithm.
CustomersPartners
growth-positive
The EVA System Colposcope Fulfills Promise of the AVE Algorithm to Change Future of Cervical Cancer Detection
MobileODT has developed an augmented intelligence algorithm called Automated Visual Evaluation (AVE) that can detect cervical cancer based on a single image. The algorithm has been validated by the National Cancer Institute and National Library of Medicine and has shown higher accuracy than traditional Pap Cytology testing. MobileODTs EVA System Colposcope is the only colposcope on the market ready to deliver AVE at the point-of-care. The company is working with the NCI and other researchers to further validate the algorithm and bring it to patients quickly. MobileODT recently announced a large-scale pilot to validate the clinical application of the AVE algorithm with partners Genworks Health and Apollo Hospitals in India. The pilot will screen up to 250 women daily.
CustomersPartners
growth-positive
MobileODT and Partners to Launch First Wide-Scale Deployment of AI screening for Cervical Cancer
MobileODT, in partnership with Genworks and Apollo Hospitals, will pilot the use of its smart mobile colposcope in India for cervical cancer screening. The partnership aims to provide low-cost mobile technology to reach millions of women in India who have limited access to cervical exams. The EVA System, developed by MobileODT, uses AI capabilities and improved workflow to enhance access to cervical cancer screening. The pilot study will be conducted at Apollo Hospital Centres throughout India and will validate the algorithm used in cervical cancer detection. The study will screen up to 250 women each day and aims to improve patient tracking and early detection of cervical cancer. MobileODT is a company that focuses on enhancing womens health through early cancer detection.
Partners
Unknown
New technology for sexual assault victims launched at Penn Highlands Dubois
A technology new to Pennsylvania thats enhancing care for sexual assault victims launched in Clearfield County.
growth-positive
India-Israel collaborate to strengthen sectors of agriculture, health and environment
Six Israeli startups with innovative technologies in healthcare, agriculture, and water management interacted with Indian businesses during the India-Israel Innovation Bridge. The bridge, managed by the Israel Innovation Authority, aims to help Israeli companies develop and commercialize their innovations in India. The partnership between India and Israel has been growing, with visits by prime ministers and presidents of both countries. The two countries have also signed an agreement to start an innovation fund. India has become one of the largest trading partners for Israel, and the startup ecosystem in both countries has seen significant growth through bilateral collaborations.
Partners
growth-positive
Young Turks: MobileODT, taking cancer screening to remote locations
The article discusses MobileODT, a company founded in 2012 that uses smartphone-like devices to detect cancer and other diseases. They have created medical devices and affordable healthcare solutions, particularly in the area of cancer detection. The companys product, Enhanced Visual Assessment (EVA), is a smart colposcope that is portable, offers detailed visualization, and has a secure data management system. It can also be used as a tele-medicine platform. The article highlights the positive impact of MobileODTs innovations in the healthcare industry. The key issues discussed in the article are related to customers and partners. The specific partners and customers are not mentioned in the article. The date of the event described in the article is not provided.
CustomersPartners
Indo-Israel collaboration brings 6 young, innovative Israeli startups to India
growth-positive
MobileODT Technology Improves Cervical Cancer Detection Rates - Study
A World Bank/IFC-funded study by MobileODT and Apollo Hospitals has found that the use of the EVA (Enhanced Visual Assessment) System in primary cervical cancer screenings leads to a higher detection rate of suspected precancerous and cancerous lesions in women. The study assessed the EVA Systems effectiveness across India, with 567 women screened for cervical cancer. The EVA System was found to be a quick and easy way to evaluate the cervix, and was highly rated by gynecologists for its feasibility, usability, and patient satisfaction.
PartnersCustomers
growth-positive
http://www.israeldefense.co.il/en/node/32654
Israeli Prime Minister Benjamin Netanyahu is leading a trade task force to India to deepen political, cultural, and business ties between the two countries. The visit aims to strengthen India-Israel relations, particularly in areas such as water, agriculture, energy, culture, innovation, and defense. Israel is a top supplier of weapons to India, with defense deals worth over $2 billion in 2017. The visit includes talks on various issues and the signing of bilateral agreements in fields like energy, cybersecurity, agriculture, homeopathy, and film production. Israel is also set to invest over $68 million in boosting Israel-India cooperation in tourism and innovation. Additionally, 18 Israeli startups have been selected for the India-Israel Innovation Challenge, focusing on agriculture, water technology, and digital health.
PartnersInvestment
growth-positive
Interview: MobileODT using AWS cloud to save lives
MobileODT, a company focused on creating smart medical devices, is using AWS cloud infrastructure to detect cancer and improve healthcare in Africa. Their EVA System combines the diagnostic accuracy of a colposcope with AWS cloud-based communication and the processing capacity of mobile phones. The system allows remote practitioners to conduct visual assessments and share them with healthcare workers for expert-level diagnosis. MobileODTs technology aims to reduce the incidence of cervical cancer and improve health outcomes for women in remote areas of Africa. The biggest challenges in implementing this technology include limited healthcare infrastructure and human resources. However, the company believes that within the next decade, connected clinicians using their technology will be common practice worldwide.
CustomersPartners
https://www.marketwatch.com/press-release/vizient-inc-announces-mobileodt-as-the-2017-innovation-challenge-winner-2017-09-14
growth-positive
Cancer diagnostic co MobileODT raises $6.85m
Israeli cancer diagnostic company MobileODT has completed a $6.85 million financing round led by OrbiMed Advisors LLC, bringing its total funding to $13 million. The company has developed a portable and inexpensive colposcopy device called EVA, which uses powerful light and a smart information analysis system to detect cervical cancer. The device is already being sold in the US, and the funding will be used to expand the companys business. MobileODT is focused on making medical testing available to larger markets, particularly in developing countries where routine testing for cervical cancer is lacking.
InvestmentExpand
http://www.geektime.com/2016/12/21/mobileodt-gets-fda-approval-for-phone-based-cervical-cancer-detection-system/
growth-positive
Mobile cancer screening device could save women's lives
Tel Aviv-based MobileODT has donated 20 of its Enhanced Visual Assessment (EVA) systems to health providers in Nyeri County, Kenya, for the Ministry of Health’s nationally sponsored screening camp. The EVA system, which uses a mobile phone and internet connection, allows for cervical cancer screenings in areas lacking more sophisticated medical infrastructure. The company has also begun providing its device to obstetrician/gynecologists in Afghanistan, in partnership with Rotary International.
CustomersExpand
growth-positive
Global Good and MobileODT Team Up to Prevent Cervical Cancer
Intellectual Ventures Global Good and MobileODT have announced a partnership to develop a new version of MobileODTs cervical cancer screening device. The device combines a cell phone with a special light and other features to make it easier for health workers to examine a womans cervix for signs of cancer. Global Good will create an algorithm to identify potential cancers and guide health workers in confirming a diagnosis. The device is already being used in several countries, and the partnership aims to make it even easier to use. The article highlights the importance of early detection and treatment of cervical cancer, particularly in developing countries where it is a leading cause of cancer deaths for women.
Partners
growth-positive
Cervix "selfies" could improve women's health care in remote regions Design Indaba
Israel-based medical company MobileODT has launched a new mobile colposcope that allows any smartphone to perform cervical cancer screenings. The device is less invasive than a Pap smear and is better suited for low-income areas. It costs $1,800 and is already being used in 11 countries. MobileODT was the winner of the 2015 MedTech Innovator competition.
CustomersPartners
growth-positive
MobileODT wins MedTech Innovator contest
MobileODT, an Israeli startup that uses mobile phones to detect cancer and other diseases, has won the 2015 MedTech Innovator competition. The company beat out 300 early medtech startups and received a cash prize of $200,000. The winners were announced at the AdvaMed 2015 conference. Briteseed, MedAware, and uBiome were the runners-up in the contest.
Investment
growth-positive
Israeli Firm MobileODT Develops Inexpensive, Smartphone-Based...
MobileODT, an Israeli startup, has developed a portable diagnostic tool for detecting cervical cancer. The company aims to provide affordable and practical healthcare innovation to improve early cancer detection. Their Mobile Colposcope device attaches to a mobile phone and relays images to a mobile app for interpretation. The device has received positive responses in pilot markets around the world. MobileODT has partnered with leading organizations and medical institutions in 14 countries. The companys technology has the potential to revolutionize cervical cancer screening and diagnosis, particularly in low-resource settings where access to screening is limited.
Customers
growth-positive
Diagnosing cervical cancer with a smartphone
MobileOCT, a company that has developed a low-cost imaging device for cervical cancer screening, is making a positive impact on the companys growth. The device transforms a smartphone camera into a colposcope, allowing community healthcare workers to detect and treat cervical cancer without the need for electricity or running water. The company is also developing diagnostic solutions for oral and skin cancer. They have partnered with various organizations to distribute the devices in countries such as Kenya, Botswana, Haiti, Mexico, and the United States. Pending positive results from clinical trials, the company plans to add optical biopsy capability to the device. MobileOCT is focused on providing accessible and affordable healthcare solutions to low-resource areas.
Customers
growth-positive
MobileOCT: The Incredible Social Startup That Uses Mobile Phones To Detect Cervical Cancer In Third-World Women
Israeli startup MobileOCT is using mobile phones to detect cancer in low-resource settings. They are developing a mobile colposcope that can be used with any mobile phone to screen for cervical cancer. The device is expected to be sold at a price point of $400, making it more affordable than traditional colposcopes. MobileOCT aims to improve the accuracy of cervical cancer detection and provide access to reliable medical equipment in developing countries. The company has partnerships with global health organizations and has raised $225,000 in funding. Their goal is to provide affordable and accessible healthcare while also being a successful business.
Customers
MobileODT Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 10 |
| Team members | 3 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 10 classification IDs that could be used for matching.
MobileODT Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 101/100 |
| Missing | markets |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 514830314 |
| Crunchbase | mobileoct |
| Phone | +97237575959 |
| Creator | Rebecca Mack |
| Creator email | rebeccamack26@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2022-11-25T00:00:00.000Z |
| Created | 2014-06-25T00:00:00.000Z |
| Claimed | Yes |